TeamDrive
RUS

NovaMedica

www.novamedica.com

NovaMedica is a modern Russian pharmaceutical company established in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceutical products and technologies as well as at development and implementation of own R&D-projects.

NovaMedica owns intellectual property rights within Russia and the CIS for 36 innovations which are part of the portfolio of RusnanoMedInvest, venture capital foundation. These are drugs for antivirus and anti-inflammatory therapy, to cure ophthalmic diseases and epilepsy as well as innovative technologies to detect oncological and infectious diseases.

NovaMedica also develops a pipeline of its own drug products. R&D Division of the company plans to develop about 15 own drugs by 2022. Five out of them are already on the different stage of development – from creation of a drug formulation up to clinical trials and state registration, and four more are on the stage of launch. These are drugs to cure disease in the sphere of gastroenterology, pain treatment, neurology, ophthalmology and rheumatology.

In April 2017 NovaMedica launched the Technology Center with state-of-the-art technological capabilities which were previously unobtainable in the Russian pharmaceutical industry.

In 2016 NovaMedica became the key partner of Pfizer in Russia. Within the frameworks of this partnership NovaMedica stared construction of a pharmaceutical GMP-facility in the Kaluga region in May 2017. 

NovaMedica possesses a well-developed infrastructure to market promotion and selling of pharmaceutical products. 

Media Center

  • 23 November 2017

    Registration of medicines in EAEU will be performed online

    The Eurasian Economic Union (EAEU) is completing the development of a unified information system that will facilitate the registration of medicinal products by businesses in the common market and provide complete information about these drugs to consumers.

  • 23 November 2017

    Kaluga Pharmaceutical Cluster received silver certificate of Cluster Excellence

    In the period of October 24 – 26, 2017, the Association of Kaluga Pharmaceutical Cluster passed the procedure of the on-site audit conducted by the experts of the European Secretariat for Cluster Analysis. The procedure included the evaluation of the cluster management system and core activities  using 30 indicators in accordance with the methodology of the European Cluster Excellence Initiative. The assessment score of the Association of Kaluga Pharmaceutical Cluster performance for more than 70% of these indicators have significantly exceeded the required values. 

  • 22 November 2017

    After unexpected tie, Amsterdam wins ‘coin toss’ for new EMA HQ

    Well, that was unexpected. The EU’s third and final vote on the new location of the European Medicine Agency tied between Milan and Amsterdam, with Amsterdam winning the proverbial coin toss tie-breaker (EU officials drew the city’s name out of a bowl).

  • 22 November 2017

    With only 2 warnings in 2017, pharma's ad police hits historic low

    As the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency's thinking and guidance on marketing communications. But this year, there’s not much to review.

Read more